Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin by Garbowski, MW et al.
Residual erythropoiesis protects against myocardial 
hemosiderosis in transfusion-dependent thalassemia by lowering
labile plasma iron via transient generation of apotransferrin
by Maciej W. Garbowski, Patricia Evans, Evangelia Vlachodimitropoulou, Robert Hider
and John B. Porter 
Haematologica 2017 [Epub ahead of print]
Citation: Garbowski MW, Evans P, Vlachodimitropoulou E, Hider R and Porter JB. Residual erythropoiesis
protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma 
iron via transient generation of apotransferrin. Haematologica. 2017; 102:xxx
doi:10.3324/haematol.2017.170605
Publisher's Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science.
Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that
have completed a regular peer review and have been accepted for publication. E-publishing
of this PDF file has been approved by the authors. After having E-published Ahead of Print,
manuscripts will then undergo technical and English editing, typesetting, proof correction and
be presented for the authors' final approval; the final version of the manuscript will then
appear in print on a regular issue of the journal. All legal disclaimers that apply to the
journal also pertain to this production process.
 Copyright 2017 Ferrata Storti Foundation.
Published Ahead of Print on June 22, 2017, as doi:10.3324/haematol.2017.170605.
  
 Thalassemic erythropoiesis, LPI, and cardiac iron  
 
 
  
1
Title Page 
 
Title: 
Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-
dependent thalassemia by lowering labile plasma iron via transient generation of 
apotransferrin. 
 
Names of authors: Maciej W. Garbowski1,2, Patricia Evans1, Evangelia 
Vlachodimitropoulou1, Robert Hider3, and John B. Porter1,2 
 
Authors’ affiliations:  
1Research Haematology Department, Cancer Institute, University College London, 
UK  
2University College London Hospitals, London, UK 
3Institute of Pharmaceutical Sciences, King’s College London, UK 
 
Running heads: 
Thalassemic erythropoiesis, LPI, and cardiac iron. 
 
Contact information for correspondence: Dr Maciej Garbowski, Research 
Haematology Department, UCL Cancer Institute, Paul O’Gorman Building, 72 
Huntley Street, WC1E 6BT, London, UK, maciej.garbowski@ucl.ac.uk, phone: +44 
207 679 6233, fax +44 207 679 6224 
 
Word count 
Abstract 249 
Main text 3994 
Number of tables 1 
Number of Figures 5 
Number of references 50 
Online supplement 1 
 
Acknowledgements 
The authors would like to thank Dr. Sukhvinder Bansal from the Department of 
Pharmacy at King’s College London for performing the hepcidin assay. MG would 
like to thank Dr. Farrukh Shah for co-supervision of Ph.D.; British Society for 
Haematology, Sickle Cell Society and UK Thalassaemia Society for the 
Haemoglobinopathy Fellowship Grant, as well as Leukaemia and Blood Diseases 
Appeal for grant support. JP would like to thank UCL Biomedical Research Centre 
for Cardiometabolic Programme support. All authors also would like to thank 
Wellcome Trust for grant support (WT093209MA). 
 
  
 Thalassemic erythropoiesis, LPI, and cardiac iron  
 
 
  
2
Abstract 
 
Cardiosiderosis is a leading cause of mortality in transfusion-dependent 
thalassemias. Plasma non-transferrin-bound iron and its redox-active component, 
labile plasma iron, are key sources of iron loading in cardiosiderosis. Risk factors 
were identified in 73 patients with or without cardiosiderosis. Soluble transferrin 
receptor-1 levels were significantly lower in patients with cardiosiderosis (odds 
ratio 21). This risk increased when transfusion-iron loading rates exceeded the 
erythroid transferrin uptake rate (derived from soluble transferrin receptor-1) by 
>0.21mg/kg/d (odds ratio 48). Labile plasma iron was >3-fold higher where this 
uptake rate threshold was exceeded, but non-transferrin-bound iron and transferrin 
saturation were comparable. Cardiosiderosis risk was also decreased in patients with 
low liver iron, ferritin and labile plasma iron, or high bilirubin, reticulocyte counts 
or hepcidin. We hypothesized that high erythroid transferrin uptake rate decreases 
cardiosiderosis through increased erythroid re-generation of apotransferrin. To test 
this, iron uptake and intracellular reactive oxygen species were examined in HL-1 
cardiomyocytes under conditions modelling transferrin effects on non-transferrin-
bound iron speciation with ferric citrate. Intracellular iron and reactive oxygen 
species increased with ferric citrate concentrations especially where iron-to-citrate 
ratios exceeded 1:100, i.e. conditions favoring kinetically labile monoferric rather 
than oligomer species. Excess iron-binding equivalents of apotransferrin inhibited 
iron uptake, decreased intracellular reactive oxygen species and labile plasma iron, 
under conditions favoring monoferric species. In conclusion, high transferrin iron 
utilisation, relative to the transfusion-iron load rate, decreases the cardiosiderotic 
risk. A putative mechanism is the transient re-generation of apotransferrin by an 
active erythron, rapidly binding labile plasma iron-detectable ferric monocitrate 
species. 
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Introduction 
 
Cardiosiderosis or myocardial hemosiderosis (MH) is a leading cause of mortality 
in transfusion-dependent thalassemias1. Suggested risk factors for MH and/or 
consequent cardiomyopathy have included: sustained high serum ferritin levels2, 
high liver iron concentrations (LIC)3, poor chelation adherence4, as well as genetic 
susceptibility factors5. However, while improved monitoring by cardiac MRI and 
improved use of iron chelators6 have led to falling frequencies of MH judged by 
cardiac MRI, there remains a variable prevalence between populations7 and between 
individuals that is not fully understood.  
 
The conduit through which MH develops is plasma non-transferrin-bound iron 
(NTBI), as transferrin-mediated iron uptake by cardiomyocytes is relatively 
'insignificant'8. NTBI is detectable as chelatable iron9,10 or redox-active iron (labile 
plasma iron, LPI)11 at transferrin saturations >75% for NTBI12 or 100% in the case 
of LPI13. Animal data suggest that NTBI is taken into myocardium through the L-
type calcium channels14, supported by recent clinical data where MH was inhibited 
in transfusion-dependent thalassemia patients by the calcium channel blocker 
amlodipine15. Plasma NTBI is not a single entity, however, being a heterogeneous 
multispeciated pool of ferric iron (not bound to high-affinity transferrin iron-binding 
sites) containing monomeric, oligomeric, and polymeric iron citrate species16 with 
weak albumin binding17, or stronger binding, where post-translational modifications 
to albumin occur18. There are a number of potential non-protein ligands for NTBI, 
including phosphate, acetate, amino acids, pyrophosphate, and citrate. However, 
phosphate, acetate, and amino acids cannot compete with the hydroxyl ion for 
iron(III) at pH 7.4. Pyrophosphate is potentially a potent iron(III) ligand but has a 
vanishingly small concentration in plasma after accounting for the effect of 
magnesium and calcium binding, thus citrate is the dominant ligand. The iron-to-
citrate ratio determines the mix of species present. As plasma citrate is roughly 
constant at 100µM, the iron-to-citrate ratio is determined by the plasma NTBI 
concentrations. At 1µM NTBI the citrate excess is 100-fold and chelatable iron 
citrate species predominate, whereas, at ≥10µM NTBI, the proportion of chelatable 
iron drops substantially17,19. LPI refers to the redox-active fraction of NTBI, hence 
its term ‘labile’, which is chelatable20, and has been implicated in organ 
hemosiderosis21. Its chemical nature is not characterized, although it is predicted to 
comprise both monomeric and oligomeric ferric citrate, albumin iron complexes, 
and possibly partially coordinated iron chelates, e.g. of deferiprone22, that are able 
to form hydroxyl radicals in presence of ascorbate and hydrogen peroxide. 
  
The balance between the rate of transferrin iron utilisation by the erythron and 
transfusion iron loading rate is key to determining levels of plasma NTBI23. Blood 
transfusion delivers a mean of 0.4mg/kg/day but with a wide range (0.2-
0.6mg/kg/day)24, exceeding by 10-fold the gut iron loading rate seen in non-
transfusion-dependent thalassemia25. Transfused red cells are ultimately catabolised 
within macrophages of spleen, liver, and bone marrow, with iron released onto 
transferrin and -- when the latter approaches saturation -- forming plasma NTBI. 
Transferrin iron uptake by the erythron via transferrin receptor-1 (TfR1) liberates 
iron from transferrin during receptor-mediated endocytosis, whereupon iron-free 
apotransferrin is recycled back to plasma, for a detailed review, see Gkouvatsos et 
al 201226. The extracellular domain of the transferrin receptor-1 is shed by red cell 
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progenitors and circulates bound to holotransferrin (sTfR1)27. TfR1 expression in 
the erythron is transcriptionally regulated such that levels increase in iron 
deficiency28. However, in thalassaemias, sTfR1 levels primarily reflect the degree 
of expansion of the erythron29–31. Blood transfusion suppresses expansion and 
activity of the erythron, thereby decreasing sTfR1 proportionately to the pre-
transfusion hemoglobin32.  
  
In this paper, we have examined clinical factors associated with MH as well as the 
mechanisms underlying these associations. In particular, we have focussed on how 
transferrin-iron utilisation by the erythron marked by sTfR1, relative to the 
transfusion-iron loading rate, impacts on the risk of MH. We have considered how 
apotransferrin formed after endocytosis in the bone marrow may bind NTBI species, 
decreasing their availability for myocardial uptake.  
 
Methods 
Patients 
A cohort of 73 transfusion-dependent thalassemia patients on deferasirox, with 
known transfusion-iron load rate24, was divided into those with MH (n=24, cardiac 
T2*<20ms, R2*>50s-1) and those without MH (n=49, T2*>20ms, R2* <50s-1)33. 
Details are provided in the Supplement. Patients gave written informed consent to 
participate in the study and approval was obtained from The Joint University 
College London/University College London Hospitals Committees on Ethics of 
Human Research. 
 
Biomarkers  
Pre-transfusion samples were tested, after a 48-hour washout from deferasirox 
chelation, for iron metabolism and routine biochemical variables, and compared in 
both groups (±MH). These included assays for NTBI9, LPI11, hepcidin, urea-gel 
transferrin saturation, sTfR1, GDF-15 as published previously23, as well as routine 
clinical variables (hemoglobin, absolute reticulocyte count, nucleated red cells, 
serum ferritin, bilirubin, and serum iron), with further details in the Supplement. 
 
Cell-line experiments 
Murine HL-1 cardiomyocytes (ATCC number CRL-12197) were grown in 
Claycomb medium (Sigma); the culture protocol is described in the Supplement. 
Buffered ferric citrate17,16 or ferric ammonium citrate was used to model NTBI. 
Ferric nitrilotriacetate (Fe-NTA) was used to saturate transferrin. Total cellular iron 
was assayed by ferrozine. The level of cytosolic reactive oxygen species (ROS), 
tested using 2,7-dichlorofluorescein diacetate (H2DCF-DA), was calculated from 
slopes of fluorescence-versus-time data. Detailed methods are provided in the 
Supplement. 
 
Statistics  
Continuous data was presented as mean±SD or median±interquartile range and 
compared using the t-test or nonparametric tests, depending on assumed distribution, 
unless otherwise specified. Categorical variables were compared using χ2-test. A 
p<0.05 was statistically significant.  
 
 
Results 
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Factors associated with MH. 
To determine factors associated with MH, biomarkers were compared in 
transfusion-dependent thalassemia patients with (n=24) and without (n=49) MH. 
The sTfR1 emerged as the factor most significantly associated with MH (p<0.001, 
Figure 1A-C) being >3-fold higher in controls than in MH (medians 4.06 vs. 
1.26µg/mL, p=0.0005) with an area-under-curve for the receiver operating 
characteristic curve (AUCROC) of 0.8, p=0.0004.  A threshold of 1.77µg/mL was 
predictive of MH with 89.7% sensitivity, 64.7% specificity (normal range for 
sTfR1: 0.3-1.65µg/mL). Other biomarkers significantly associated with MH were 
bilirubin, reticulocyte count, hepcidin, LIC, and serum ferritin (Table 1). Although 
median LPI differed insignificantly between MH and non-MH patients, a cut-off 
threshold of >0.31µM was significantly associated with MH (χ2 p=0.04). 
Differences in NTBI, LPI, transferrin saturation (TfSat), and transfusion iron load 
rate (ILR) were insignificant (Figure 1D-G), and no such thresholds were found for 
NTBI or TfSat. 
 
High liver iron concentration and, to a lesser extent, serum ferritin are also 
significant risk factors for MH in our study, which is of interest, as this was not seen 
in earlier studies33. However, liver iron determination in earlier studies was not 
optimal34 and many patients had recently undergone intesive iron chelation which 
removes iron faster from the liver than from the heart35, thereby obscuring such a 
relationship36. A further significant, though weak, risk factor for MH was high 
plasma hepcidin. Hepcidin did not correlate with markers of iron overload such as 
LIC (as hepatic R2*, p=0.4), or ferritin (p=0.52), but inversely correlated 
significantly to sTfR1 (Spearman r=-0.54, p<0.0001). sTfR1 did not correlate with 
LIC or ferritin (p=0.4 and 0.52, respectively; Supplement Figure 1). Insignificant 
MH associations were with nucleated red cells, total serum iron, age, weight, ILR, 
TfSat, and GDF-15.  
 
Relationship of transferrin-iron utilization to MH in transfusion-dependent 
thalassemia.  
To gain insight into the relationship between MH and sTfR1, we utilized 
understandings from ferrokinetic studies29,30 which established the erythron 
transferrin uptake (ETU) as proportional to plasma sTfR1. The regression equation 
(r2=0.84) for ETU was calculated from published data29: 
 
ETU[µmol Fe/L plasma/day]=0.013*sTfR1[µg/L]+2.25 
 
Assuming that the relationship remains temporally stable, sTfR1 represents 
erythropoiesis quantitatively, given that plasma levels are proportionate to tissue 
transferrin receptors of the whole organism31, of which erythroid cells are the main 
dynamic component. ETU can be expressed as a rate corrected for estimated blood 
volume: BV=70mL/kg (males), 65mL/kg (females), and patient weight (erythroid 
transferrin uptake rate, ETUR). 
 
ETUR[mg/kg/d]=ETU[µmol/L/d]*55.845[g/mol]/1000*BV[mL]/1000/weight[kg].  
 
Although transfusion does not directly relate to cardiac iron, when plasma sTfR1 
levels were expressed as ETUR (i.e. transferrin-iron utilization rate) and compared 
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to the transfusion ILR (Figure 2A-C), MH was present only when the ‘net ILR’ 
(ILR-ETUR) exceeded 0.21mg/kg/d (p<0.001). Above and below this threshold, 
LIC34, TfSat, and NTBI were similar (9.7 vs. 10.1 mg/g dry weight, 96 vs. 98%, 3 
vs. 2.6µM, p=ns), while LPI was >3-fold higher (0.35 vs. 0.1 µM, p=0.01). Thus, 
LPI was high only in patients where the net ILR exceeded 0.21mg/kg/d, whereas 
LIC, TfSat, NTBI showed no difference between patients with and without MH, 
even when adjusted for the net ILR (Figure 2C).  
 
This suggests a link between iron clearance from transferrin -- a process implying 
the formation of transient levels of apotransferrin -- and the low propensity to MH 
in transfusion-dependent thalassemia. We hypothesized that increased transient 
local concentrations of apotransferrin in the marrow and circulating reticulocytes37 
could decrease the uptake of NTBI into the myocardium. With similar TfSat and 
NTBI in MH-positive and MH-negative patients, this effect of recycled 
apotransferrin was expected to influence the speciation of NTBI.   
 
Effects of iron-to-citrate ratio on iron detection in the LPI assay 
 
As LPI was found to differ between MH-positive and MH-negative patients, we 
wished to characterise which fraction of NTBI was detected by the LPI assay. In 
particular, we wished to determine whether LPI was most detectable under 
conditions where either monomer or oligomer ferric citrate species predominated. In 
Figure 3A at constant citrate concentrations (100µM), the proportion of iron 
detectable in the LPI assay decreases as iron concentration increases. Conversely, 
LPI is proportionately most detectable at 1000-fold citrate excesses. Under these 
clinically relevant conditions, the citrate excess favors the formation of monomer 
rather than oligomer species. As LPI was associated with an increased MH risk in 
our clinical observations, these findings suggest that the monomer LPI might be the 
species most readily taken into myocardial cells. 
 
Effect of iron-to-citrate ratio on iron uptake into HL-1 cardiomyocytes 
 
To confirm this interpretation, we examined iron uptake in HL-1 cardiomyocytes at 
varying iron-to-citrate ratios. In Figure 3B the effect of increasing ferric iron at 
constant citrate concentration (100µM) on HL-1 uptake is shown at 24h. A clear 
plateau effect is seen whereby iron uptake does not increase further when citrate 
exceeds iron by less than 100-fold. Under these conditions oligomer rather than 
monomer ferric citrate species are favored17. This suggests that oligomer iron citrate 
species are less available for uptake by cardiomyocytes than the monomer species.  
 
Effect of iron-to-citrate ratio on iron binding to transferrin 
 
We wished to determine how the iron-to-citrate ratio also affected the availability of 
ferric iron to bind transferrin. In Figure 3C, apotransferrin (at 35.5µM or 71µM 
iron binding equivalents, IBE) was incubated with buffered ferric citrate at 0 to 
4000-fold citrate excess. Iron binding to transferrin, determined by spectroscopy, 
increased to a maximum of 40% as the citrate excess increased. Thus under 
conditions favoring monomer ferric citrate species, binding of iron to transferrin is 
more rapid than where oligomers predominate.  
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Low (nanomolar) concentration of apotransferrin substantially decreases LPI 
 
The preferential binding of the monomer ferric citrate species by transferrin was 
predicted to decrease those same species responsible for activity in the LPI assay. 
We tested this in Figure 3D, where the control without transferrin showed 
increasing LPI values with increasing ferric iron concentration (at constant 100µM 
citrate). When apotransferrin is added at remarkably low concentrations (30nM or 
60nM IBE), LPI detectability is decreased substantially across all ratios. This effect 
exceeds results expected from simple stoichiometric binding. Higher concentration 
of apotransferrin (10µM) completely abrogates LPI detectability up to 10µM iron. 
These findings show that the redox-active iron species responsible for the majority 
of LPI detectability is present at a very low concentration (nanomolar). This species 
is most likely to be ferric monocitrate because apotransferrin is known to bind ferric 
monocitrate most avidly. 
 
Effect of apotransferrin on HL-1 cardiomyocyte iron uptake from ferric citrate 
species  
 
Having established the conditions favoring LPI detectability and apotransferrin 
binding of ferric citrate species, we wanted to test whether these same conditions 
are those that most inhibit iron uptake in HL-1 cardiomyocyte cells.  
 
We first examined the effect of transferrin on uptake from ferric ammonium citrate 
(FAC), which is a stable form of monomeric ferric iron coordinated by two citrate 
molecules38. In Figure 3E it can be seen that iron uptake from 1µM FAC is almost 
completely inhibited by apotransferrin at 1µM (2µM iron binding equivalents). In 
Figure 3F, the effect of constant transferrin concentration with varying percentage 
saturations on iron uptake from 5µM FAC at 24h is examined. Uptake is completely 
inhibited by physiologically relevant transferrin concentrations of 37µM (74µM 
iron-binding equivalents) at saturations below 99%.  
 
We then wished to examine the inhibitory effect of apotransferrin on iron uptake at 
varying iron-to-citrate ratios. In order to study short-time intervals, we developed an 
intracellular ROS assay and validated this against total cellular iron at 24h (Figure 
4A). The control iron uptake marked by intracellular ROS at 60 minutes in Figure 
4B (closed circles) shows a plateau, as previously noted for total iron uptake at 24h 
(Figure 3B). Thus, under conditions where oligomer species increasingly 
predominate, uptake into HL-1 cells forms a plateau. In the same experiment 
(Figure 4B triangles), the addition of 5µM apotransferrin inhibits uptake up to the 
point where ferric citrate approaches 10µM, at which concentration iron uptake 
exceeds that from control. Importantly, this contrasts with the effects of 
apotransferrin on iron uptake from FAC (Figure 3F) where uptake was inhibited at 
every apotransferrin concentration. The key difference between Figures 3B, E and 
F is the form of iron citrate presented to the cells. Freshly prepared FAC is a fully 
co-ordinated monomeric iron dicitrate38, whereas at the 1:10 iron-to-citrate ratio 
used in Figure 3B, mixtures of oligomer and monomer iron species are present17,16.  
 
The increased uptake for apotransferrin in Figure 4B might be interpreted 
superficially as increased uptake from holotransferrin, formed from the addition of 
apotransferrin to iron citrate. However control experiments, including Figure 4C 
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and Supplement Figure 2, show that incubation of HL-1 cardiomyocytes with 
holotransferrin does not increase iron uptake: increasing concentration of 95%-
saturated transferrin actually inhibited iron accumulation.  
 
An alternative explanation for the findings in Figure 4B is that the interaction of 
apotransferrin with iron citrate alters the proportions of citrate species. To test this 
hypothesis further, we examined in Figure 4D the iron uptake at increasing 
concentrations of apotransferrin but constant iron citrate concentrations that favor 
oligomer species (10µM ferric iron and 100µM citrate). Apotransferrin between 1 
and 8µM increased iron uptake but at higher apotransferrin concentrations (8µM or 
16µM) uptake was inhibited. This is more consistent with catalytic 
depolymerisation of oligomers to monomers as elaborated in the discussion.  
 
We suggest therefore that the presence of apotransferrin in Figures 4B and D favors 
the formation of citrate species that are more rapidly taken into cells, namely 
monomeric iron species. Only when the iron binding capacity of apotransferrin 
exceeds the iron content of the ferric citrate (here above about 10µM), is iron uptake 
inhibited. We conclude that speciation of iron citrate is critical to cardiomyocyte 
iron uptake and that apotransferrin alters this speciation.  
 
 
Discussion 
 
In this paper we have sought to identfy risk factors for MH in transfused 
thalassemia patients. A key novel finding is that low levels of sTfR1 appear a 
powerful predictor for MH with an odds ratio of 21. It is unlikely that sTfR1 exerts 
a direct mechanistic role in iron distribution, as mice transfected with sTfR1 showed 
similar iron absorption and hepcidin to controls39. Furthermore, circulating 
concentration of sTfR1 (nanomolar) is three logs less than that of diferric transferrin 
and thus unlikely to be a significant receptor trap for transferrin iron utilisation. We 
also found a clear relationship between the transfusion-iron loading rate and the 
myocardial iron by MRI (mR2*) in MH(+) patients (Figure 2B). This suggested 
that the balance between the transfusion iron-loading rate and erythron iron 
utilization might be key to MH. We therefore developed a model building on data 
linking sTfR1 to quantitate iron utilization by the erythron (the ETUR)29,30, and  
found that the difference between the ILR and the ETUR predicted MH with an 
odds ratio of 48. We identified a threshold for this difference of 0.21mg/kg/day, 
above which MH was more likely and below which MH was not seen (Figure 2C), 
even in the presence of high total body iron (Figure 2D). Hence a high transfusion 
iron intake relative to endogenous erythropoiesis puts patients at increased risk of 
MH.  
 
The high transfusion iron intake relative to endogenous erythropoiesis as a risk for 
MH is supported by other clinical observations. Additional factors that we found 
correlated with lower MH risk, such as high bilirubin and high reticulocytes, are 
also consistent with a high activity of the erythron. Others have shown that 
reticulocyte count below 5% in sickle cell disease was actually found to predict 
premature development of cardiac iron deposition40. Erythropoietin, although not 
measured in this cohort, would be predicted to negatively correlate with MH 
because it drives sTfR1 levels29 and correlates with them closely in transfusion-
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dependent thalassemia. The relationship of the age of onset of transfusion 
dependence to MH suggests that an initial expansion of the bone marrow, by under-
transfusion or late introduction of transfusion, is hard to suppress even after many 
subsequent years of hypertransfusion (Supplement Figure 3). Others have 
indirectly linked the absence of MH with extramedullary hematopoiesis in 
transfused thalassemia patients, using extramedullary masses by MRI as surrogate 
markers of erythroid mass41, which also proves the point that even life-long 
hypertransfusion does not suppress erythropoiesis completely. A high risk of MH 
has also been identified in another transfusion-dependent condition with low iron 
utilisation and extremely low sTfR1, namely Diamond-Blackfan anemia23,42. 
Conversely, non-transfusion-dependent thalassemia patients have very high sTfR1 
levels13 with high ineffective erythropoiesis but a low risk of MH43,44, despite 
substantial iron overload. Factors in addition to iron uptake may influence net MH. 
For example, our findings of increased plasma hepcidin in MH-positive patients are 
consistent with recent work in animal models of iron overload implicating iron exit 
through cardiac ferroportin channels as important to myocardial iron retention45,46. 
There was a significant relationship between hepcidin and sTfR1, but not with 
GDF15, nonetheless it would be of value to look at this relationship with 
erythroferrone when the assay becomes available.   
 
What is the role of the labile plasma iron fraction of NTBI in MH risk? A notable 
feature of non-transfusion-dependent thalassemias, reported elsewhere on a large 
cohort of 155 patients, is that, even in the presence of high levels of body iron and 
raised NTBI, LPI is typically within the normal range, while the few cases with 
increased LPI have no apotransferrin13. This is consistent with this paper's findings 
in trasfusion-dependent patients where a >3-fold difference in LPI was seen across 
the ILR-ETUR threshold, while plasma NTBI levels and transferrin saturations 
were indistinguishable (Figure 2C). This suggests that LPI-detectable species are 
those taken up by cardiomyocytes, consistent with previous clinical observations 
linking LPI-detectable iron to MH21.   
 
As the LPI assay detects only the redox-active sub-fraction of NTBI, we wished to 
determine whether LPI-detectable NTBI species were those particularly prone to 
cardiomyocyte uptake. We used buffered ferric citrate as a model for NTBI at 
constant citrate of 100µM to represent plasma concentration. Detectability of iron 
by the LPI assay was less using iron citrate as the source of iron than Fe-NTA 
(Supplement Figure 4), indicating that only a proportion of ferric citrate species 
are detectable by the LPI assay. Furthermore, LPI was proportionately most 
detectable when citrate exceeded ferric iron concentrations by >100-fold; ratios 
known to be associated with the appearance of monoferric citrate species17,16. We 
therefore hypothesised that monoferric species are taken into cardiomyocytes most 
readily since, in our study, MH associates with LPI, rather than with total NTBI. 
Monoferric species include ferric monocitrate and ferric dicitrate17,16 (Figure 5, 
compounds A and C). Redox-cycling of iron species is dependent on the ability of 
reductants and oxidants to gain access to the iron center by displacing the 
monodentate water molecules which occupy the ‘free’ coordination sites of iron 
complex that is only partially coordinated by ligands such as one tridentate citrate 
molecule or one bidentate deferiprone molecule22 (Figure 5, coordination sites in 
bold). Ferric dicitrate, with its iron center fully hexa-co-ordinated by two tridentate 
citrate molecules, has a high stability constant for iron(III)16, is less redox-active22, 
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thus less of a candidate for uptake (a process requiring reduction14,47,48). We 
predicted therefore that it is ferric monocitrate which is most available to 
cardiomyocyte uptake as well as to transferrin binding, as discussed below.  
 
We found that the cardiomyocyte iron uptake from citrate and its inhibition by 
apotransferrin are speciation-dependent. Cardiomyocyte uptake of ferric citrate 
indeed occurred most rapidly where citrate excess was high (Figure 3B), under 
conditions favoring monomer rather than oligomer species. This contrasts with 
previous reports for hepatocytes and cardiomyocytes8,47,49 using Fe-NTA, a non-
physiological but typically monomeric iron source, where the speciation 
dependence of uptake was not studied. 
 
Very low concentration of apotransferrin, and transferrin saturations ≤99% inhibited 
cardiomyocyte iron uptake from ferric ammonium citrate (Figures 3E and F). This 
suggests that the NTBI species partaking in cardiac uptake constitute only a small 
fraction of the total NTBI. The small magnitude of this fraction is consistent with 
monocitrate being the predominant species for cardiomyocyte iron uptake. Furthermore, 
because apotransferrin decreases LPI in our assays, and iron monocitrate is the species 
most rapidly chelated by apotransferrin, as described above, ferric monocitrate is most 
likely the predominant LPI species. Very low transferrin concentrations (nanomolar) 
were all that were necessary to inhibit LPI-detectable iron citrate species (Figure 
3D), which we identified above as being monoferric citrate. This suggests that this 
LPI-detectable species is present at very low concentration but is kinetically labile.  
 
Surprisingly, we found that at very high ferric citrate concentrations (10µM, Figure 
4D), under conditions that favor oligomer species, rarely observed clinically, sub-
stoichiometric concentrations of apotransferrin, insufficient to bind all the ferric 
citrate, actually increased cellular iron uptake. This is not due to increased uptake 
by holotransferrin, as negligible iron was delivered to cardiomyocytes by 
holotransferrin (Figure 4C), consistent with previous observations in 
cardiomyocytes8. We deduced therefore that increased uptake from ferric citrate in 
the presence of apotransferrin under these conditions may occur by accelerating the 
dissociation of oligomer to monomer citrate species (Figure 5). This deduction is 
consistent with the observation that the transition from absence to excess of 
transferrin binding capacity is associated with the generation of kinetically labile 
iron citrate species that are rapidly taken into HL-1 cardiomyocytes (Figure 4D). 
This effect is notable only when apotransferrin is present at intermediate 
concentrations allowing depolymerisation of oligomers to their constituent 
monomers (i.e. ferric monocitrate, see Figure 5). Previous work, consistent with 
this model, showed that the rate-limiting step for exchange of polymeric ferric citrate 
iron with apotransferrin was the de-polymerization and release of monomeric 
(mononuclear) ferric citrate50. Ferric dicitrate was unreactive towards apotransferrin 
unless converted to an active intermediate, which the authors had supposed to be the 
monocitrate50. Importantly, such conditions of very high NTBI are unlikely to occur 
clinically so that inhibitory effects of apotransferrin on NTBI uptake will 
predominate.  
 
In conclusion, we propose a mechanism of MH inhibition by the generation of 
apotransferrin during erythropoiesis. Taken together our clinical and in vitro data point 
to increased generation of apotransferrin by an active bone marrow (marked by high 
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sTfR1) as a key mechanism for decreasing the MH risk in transfusion-dependent 
thalassemias. We suggest that a local excess of apotransferrin in the bone marrow, 
around sinusoids and reticulocytes, chelates monomeric ferric citrate species, the same 
species most rapidly taken into the myocardium. The clinical implications of this are 
that a critical balance appears here to exist between the transfusion rate, endogenous 
erythropoiesis, MH risk and NTBI speciation. We suggest that prospective longitudinal 
data collection, including sequential sTfR1 measurement, would be valuable so that 
clear recommendations could be made about whether reducing transfusion exposure 
decreases the MH risk. Furthermore, due to the marked geographic variability in MH 
risk7 that cannot be related solely to chelation practices, cross-sectional studies on the 
impact of regional transfusion policies on ETUR and MH risk could be indicated. 
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Tables 
Table 1. Significant clinical and laboratory variables associated with MH in TDT.  
variables threshold  OR±SE p value MH(-) MH(+)  p-value  
Chelation start age [yr] ≥7.5 8.42±0.81 0.009 7.5 (3.5-12) 2.5 (2-6) 
0.0039 
Age [yr] ≥35.92 5.9±0.61 0.005 35.67 ± 10.57 32.11 ± 6.92 
0.12 
Un-chelated transfusion years [%] ≥5 4.68±0.6 0.018 8 (3-18) 4.5 (3-9) 
0.15 
Transfusion dependency start age [yr] ≥1.5 3.64±0.58 0.046 1.5 (0.67-5.5) 0.9 (0.5-1.88) 
0.02 
ETUR-ILR [mg/kg/d] <0.21 48.4±1.15 0.00008 0.09 (-0.08-0.17) 0.27 (0.24-0.34) 
0.0002 
Total bilirubin [µM] ≥16.5 21±1.1 0.0014 35 (25-52) 22 (14-29.75) 
0.0004 
Hepatic R2* [s
-1
]  <142
1
 21±1.06 0.0007 139 (79-365) 326 (235-625) 
0.003 
sTfR1 [mg/mL] ≥1.34 20.81±0.87 0.00016 4.06 (2.55-5.95) 1.26 (0.68-2.71) 
0.0003 
ETU [mgFe/L whole blood/day] ≥1.45 16.04±0.73 0.0001 14.06 (6.53-18.26) 3.89 (1.82-4.86) 
0.0001 
Absolute reticulocyte count  [×109/L] ≥7.4 13.75±1.14 0.02 44.4 (19.95-128.9) 20.6 (7.1-30.7) 
0.029 
LPI [µM] <0.31 10.5±1.02 0.04 0.1 (0.02-0.17) 0.27 (0.05-0.45) 
0.13 
Hepcidin [nM] <6.78 9±0.81 0.006 6.8 (3.18-22.13) 14.3 (7.58-23.65) 
0.04 
Ferritin [µg/L] <1700 7.63±0.62 0.001 1309 (844-3057) 2926 (1958-4284) 
0.0013 
Medians with 25th-75th percentile range or mean ± SD are provided for MH(-) and MH(+) groups, 
compared with Mann-Whitney or t-test, as well as threshold protecting from MH and its odds ratio 
(OR). 1LIC=4.41mg/g dry weight34. [yr]=years. 
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Figure legends 
 
Figure 1. Biomarkers in patients with and without myocardial siderosis. 
Comparison of means and medians in patients with and without cardiac iron, MH(+) 
and MH(-), respectively, shown as box and whisker (min-max) plots. (A) Soluble 
transferrin receptor-1, sTfR1: 4.06 vs. 1.26µg/mL, MW p=0.0005. (B) Receiver 
operating characteristic (ROC) curve for sTfR1, AUCROC=0.8±0.07 (p=0.0004). (C) 
Plot of cardiac R2* vs. sTfR1, Spearman correlation coefficient r = –0.61, 
p<0.0001. (D) Non-transferrin-bound iron, NTBI: 2.86 vs. 2.7µM, MW p=0.59. (E) 
Transferrin saturation, TfSat: 100 vs. 100%, MW p=0.94. (F) Labile plasma iron, 
LPI: 0.1 vs. 0.27µM, MW p=0.13. (G) Transfusion-iron load rate, ILR: 0.32 vs. 
0.35mg Fe/kg/day, t-test p=0.19. (H) Growth-differentiation factor-15, GDF15: 
6702 vs. 4430pg/mL, MW p=0.4 (I) Plasma hepcidin 6.8 vs. 14.3nM, MW p=0.04. 
MW, Mann-Whitney test; AUC, area under curve, MH, myocardial hemosiderosis. 
 
Figure 2. Balance between transfusion-iron load rate and erythroid transferrin 
uptake rate derived from sTfR1 relates to cardiac iron. (A) Cardiac R2* plotted 
against transfusion-iron load rate, grey circles mark patients with cardiac iron 
(cR2*>50s-1), open circles – patients without cardiac iron; no relationship overall. 
(B) Cardiac R2* (cR2*) plotted against transfusion-iron load rate (ILR), open 
circles mark patients with cardiac iron (cR2*>50s-1), grey circles – patients without 
cardiac iron; no relationship overall, relationship present in patients with cardiac 
iron only, r2=0.61; points differ in size accoding to sTfR1 level [µg/mL], see inset.  
(C) same as in panel B but the x-axis shows ILR corrected for utilisation rate 
derived from sTfR1 according to Beguin et al 199329 
(ETU[µmol/L/day]=0.013×sTfR1 [ug/L]+2.25; 
ETUR[mg/kg/d]=ETU×55.845[g/mol]/1000×Blood Volume[mL]/1000/body 
weight[kg]). Highly discriminant threshold 0.21mg/kg/d p<0.0001, 100% sensitive, 
83% specific for MH (PPV 71%, NPV 100%) above and below which the LIC, 
TfSat and NTBI do not differ (p=ns) but LPI is 0.35µM vs. 0.1 µM p=0.01, 
respectively. (D) same as panel C but points differ in size according to total body 
iron derived from LIC values. 
 
Figure 3.  Effect of ferric citrate speciation on LPI detectability, total cellular 
iron and transferrin binding. (A) LPI as a percentage of ferric citrate with 
constant citrate (100µM) and variable iron (0-10µM, shown next to data points in 
µM), as a function of excess citrate (fold), representative of 3 experiments. This 
illustrates what proportion of a given ratio species is LPI-detectable. (B) Total 
cellular iron dose response in confluent HL-1 cells to 24h incubation in Claycomb 
medium (CM) with ferric citrate in MOPS pH=7.4 at variable Fe:citrate ratios and 
constant citrate at 100µM, r2=0.95, EC50=0.31µM, EC90=1.09µM; shown as 
mean±SD, n=6. (C) Percentage of ferric citrate iron that binds to 35.5µM 
apotransferrin (ApoTf) to form ferrotransferrin (over 2h incubation at 37°C) as a 
function of citrate:Fe ratio. 0-30µM iron and 100µM citrate were increased 25.5-
fold to keep the same ratio (see legend: 0-765µM and 2550µM f.c. respectively) in 
order to better resolve absorbance peaks of holotransferrin formation (at 465nm, 
inset), and compared to 35.5µM 100% saturated ferrotransferrin absorbance of 1.69. 
Percentage of iron bound to transferrin was calculated from transferrin iron 
content/nominal concentrations prepared (see inset, mean±SD, n=2). (D) 
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Apotransferrin-dependent inhibition of LPI in ferric citrate. Apotransferrin (ApoTf) 
with 25mM bicarbonate was added at 0-10µM (f.c.) together with ferric citrate, 
subsequent DHR oxidation was followed up for 1 hour. LPI values are interpolated 
from the standard curve, mean±SD, n=3. (E) HL-1 cells grown to confluence and 
incubated for 24h in CM with 1µM ferric ammonium citrate (FAC) ±0-2.5µM 
ApoTf; ANOVA p<0.001, mean±SD, n=2, Bonferroni post-test significant for 
ApoTf effect in the FAC group. Global fit r2=0.91, ApoTf IC50=0.81µM, curves 
significantly different (p<0.0001). (F) Transferrin saturation-dependent model of 
NTBI uptake (as FAC) into HL-1 cells grown to confluence then incubated in CM 
with apotransferrin and 100% saturated holotransferrin at relevant ratios to obtain a 
37.5µM TfSat model ±5µM FAC; difference vs. control (no NTBI) only detectable 
for TfSat=100%, i.e. when no apotransferrin is present (multiple t-test with Holm-
Sidak correction for multiple comparisons, p=0.004, mean±SD, n=6). 
 
Figure 4. Effect of apotransferrin and citrate speciation on the iron uptake 
marked by cytosolic ROS. (A) The relationship of intracellular ROS levels by the 
DCF method and the total cellular iron by the ferrozine method, r=0.91, p<0.0001; 
Deming regression slope 1.14×10-5±1.68×10-6, intercept 2.69×10-5±5.08×10-6, 
mean±SD, n=6. (B) Cytosolic ROS levels in HL-1 cardiomyocytes as a function of 
control ferric citrate (iron 0-30µM, citrate 100µM) in MOPS pH=7.4 with 
(triangles) and without (circles) 5µM apotransferrin (ApoTf) in 25mM bicarbonate; 
mean±SD, n=5. (C) Dose response of cytosolic ROS levels in HL-1 cardiomyocytes 
to 95% saturated transferrin (0.37-15µM) ±100µM iron-binding equivalents of 
CP40, an extracellular chelator, mean±SD, n=4. (D) Cytosolic ROS formation in 
HL-1 cardiomyocytes showing recent uptake of iron from predominantly oligomer 
species (10µM iron, 100µM citrate) or control (citrate only) under dose response 
effect of 0-16µM apotransferrin in 30mM bicarbonate/PBS; mean±SD, n=4. 
 
Figure 5. Model of apotransferrin-dependent re-speciation of polymeric ferric 
citrate.  
The paradoxical effect of apotransferrin seen in Figure 4D where uptake from 10µM 
ferric citrate is increased before it is abolished by apotransferrin, is consistent with 
the sub-equivalent concentration of apotransferrin disrupting ferric citrate oligomers 
and releasing from them ferric monocitrate species. As apotransferrin binds a 
portion of iron in high ratio ferric citrate, this decreases the amount of iron per 
citrate, so effectively changes the iron-to-citrate ratio, i.e. re-speciates it. In the 
presence of apotransferrin and bicarbonate, which forms a ternary complex with 
citrate, oligomer complexes of ferric citrate become a source of ferric monocitrate 
species. These are subject to competition with uptake mechanisms for cellular entry 
(dotted line), with apotransferrin for the formation of ferrotransferrin and with 
citrate for the formation of ferric dicitrate, citrate also competing with apotransferrin 
for ferric monocitrate. Kinetic differences between ferrotransferrin formation and 
cellular uptake from ferric citrate may explain the additional iron uptake from newly 
released mononuclear species before apotransferrin can chelate them altogether. The 
coordination sites on the iron (shown in bold) are typically occupied by water, but 
they are labile sites and can also bind oxygen and H2O2, rendering the species 
susceptible to redox chemistry (marked in bold cursive on the right). They are also 
the sites of condensation with other iron complexes.  
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Supplement to  
Residual erythropoiesis protects against myocardial hemosiderosis in 
transfusion-dependent thalassemia by lowering labile plasma iron via transient 
generation of apotransferrin. 
Maciej W. Garbowski, Patricia Evans, Evangelia Vlachodimitropoulou, Robert 
Hider, John B. Porter 
 
Methods 
In order to relate cardiac iron to biomarkers in patient blood samples, cardiac MRI 
and blood biomarkers were measured at baseline and ~1.5 years later, over which 
time the transfusion iron load rate (ILR) in mg/kg/day was calculated from the 
number of blood units transfused, assuming 200mg iron per unit, patients’ mean 
weight and number of days between MRI scans1. The mean follow-up was 502.7 
days (SD 189.5), baseline mean cardiac R2* 61.14±5.8s-1, follow-up 56.96±5.19s-
1(SE). During the follow-up, the change in the mean cardiac iron level was 
significant (paired t-test p=0.011), although clinically trivial, of 4.17 s-1. The cohort 
of 73 patients with transfusion dependent thalassaemia on deferasirox was divided 
into those with MH (n=24, cardiac T2*<20ms, R2*>50s-1) and those without MH 
(n=49, T2*>20ms, R2* <50s-1)2.  
Plasma biomarkers 
A range of serum and plasma biomarkers was used in the study to test for a 
relationship with cardiac iron.  
Non-transferrin-bound iron (NTBI) was assayed using the HPLC-based 
nitrilotriacetate (NTA) method3,4. Briefly, 20µL of 800mM NTA (at pH=7) was 
added to 180µl serum and allowed to stand for 30min at 22oC. The solution was 
ultra-filtered using the 30kDa Whatman Vectaspin ultracentrifugation devices at 
12320g and the ultra-filtrate (20µL) was injected directly onto an HPLC column 
(ChromSpher-ODS, 5µM, 100x3mm, glass column fitted with an appropriate guard 
column) equilibrated with 5% acetonitrile and 3mM deferiprone in 5mM MOPS 
(pH=7.8). The NTA-iron complex then exchanges to form the deferiprone–iron 
complex detected at 460nm by a Waters 996 photo-diode array. Injecting standard 
concentrations of iron prepared in 80mM NTA generated a standard curve. The 
800mM NTA solution used to treat the samples and prepare the standards is treated 
with 20µM iron to normalize the background iron that contaminates reagents. This 
means that the zero standard gives a positive signal since it contains the added 
background iron as an NTA–complex (2µM). When unsaturated transferrin is 
present in sera, this additional background iron can be donated to vacant transferrin 
sites resulting in a loss of the background signal and yielding a negative NTBI value.   
Labile plasma iron (LPI) assay was performed in a cell-free system (on patient 
plasma in Figure 1, Figure 2 and Table 1 or on buffered solutions in Figure 3) using 
the 2,3-dihydrorhodamine (DHR) method5 with modifications as previously 
published6, which were limited to the generation of standards in plasma-like 
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medium containing 20mg/mL human serum albumin. The assay was recently used 
in an international round robin7. Briefly, in a 96-well plate, quadruplicates of 20µL 
of serum or buffered solution were added to 180µL of plasma-like medium, 
containing 20mg/mL human serum albumin and freshly added 50µM DHR with 
40µM ascorbate only for the first set of duplicates and 40µM ascorbate with 50µM 
deferiprone for the second set of duplicates. Fluorescence intensity measurements 
were taken in each well (excitation 485nm, emission 538nm) for 40 minutes, with 
readings every 2 minutes. Slopes of DHR fluorescence intensity were taken between 
15 and 40 minutes, and expressed as fluorescence intensity units per minute. The 
duplicate values of the slopes in the presence and absence of deferiprone (r1 and r2, 
respectively) were averaged and subtracted (r2-r1) for both the standards and the 
unknowns, with the LPI value of the unknowns interpolated from the standard 
curve. Standards were prepared from Fe-NTA (1:7) solutions spiked into plasma-
like-medium.  
Plasma hepcidin was assayed using mass-spectrometry8, transferrin saturation 
was measured using the urea-gel method9, sTfR1 and GDF-15 ELISAs were 
performed as before10, according to manufacturers’ specifications. Routine relevant 
haematological and biochemical biomarkers included automated absolute 
reticulocyte count, automated nucleated red blood cell count (NRBC), serum 
total bilirubin, hemoglobin, serum ferritin, and total serum iron.  
Cell-line experiments on HL-1 cardiomyocytes 
For cell-line experiments, murine HL-1 cardiomyocytes (ATCC number CRL-
12197) were grown as previously published11, on 80cm2 flasks (SLS Ltd) or 48-well 
plates (Fisher Scientific, UK) coated with 0.5mL/100mL fibronectin (F-1141) in 
0.02% gelatin (BD) in Claycomb medium supplemented with 300µM ascorbate, 
100µM norepinephrine, 2mM L-glutamine, 100U/mL penicillin, 100µg/mL 
streptomycin and 10% fetal calf serum (serum batches for HL-1 cells as defined by 
SAFC). After confluence had been achieved (24-48h), monolayers were washed 
with Claycomb medium without FCS before subsequent 24h incubation with 
experimental media (culture media without FCS). Claycomb medium contains 
1.76±0.03µM iron using ferrozine assay (see below) of which 0.8µM is transferrin 
iron, as per manufacturer’s communication that typically 0.4µM holotransferrin is 
added during media production. PBS contains 2.57±0.19µM iron using ferrozine 
assay (see below), chelexed PBS contains 0.028±0.01µM iron. 
Iron solutions for in-vitro work 
In order for ferric iron to remain in solution at physiological pH=7.4, it needs to be 
liganded to protein, typically transferrin, or other ligands in order to prevent iron 
from being coordinated by water molecules – a process that eventually leads to 
precipitation as ferric hydroxide complexes. Citrate is the most relevant 
physiological ligand for ferric iron when transferrin is fully saturated12. As a model 
of NTBI, ferric citrate buffered in MOPS pH=7.4 was used following 24h 
incubation at room temperature after its preparation to allow for species 
stabilization13,14. During its preparation atomic absorption 18.036mM ferric chloride 
standard was mixed with 80mM sodium citrate at specified ratios and left for 30 
minutes to equilibrate. Careful drop-wise addition of buffered MOPS pH=7.4, under 
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constant vortex-mixing, slowly (1-2min for each solution) increased the pH and 
then the solution was left to allow for species stabilisation. In the buffered solutions 
containing iron-to-citrate ratios of 1:3333, 1:1000, 1:333, 1:100, 1:33, 1:10, and 
1:3.3, the ferric citrate species range from predominantly ferric dicitrate (FeCit2, up 
to 1:100) through dimers (Fe2Cit2) and trimers (Fe3Cit3) and their stacks13,14. 
Because there exists a relationship between iron-to-citrate ratios in the solution and 
the predominant species present, i.e. that ratio determines the ferric citrate 
speciation, we also refer to the species by stating the relevant causal iron-to-citrate 
ratio, e.g. 1:100 species typically indicates a monomeric species such as the ferric 
dicitrate species FeCit2, since under pH=7.4 it is the predominant form of ferric 
citrate present in 1:100 iron-to-citrate ratio solutions. We prepared ferric citrate 
solutions with constant citrate (at physiological concentration of 100µM). After 
species stabilization (i.e. at 24h from preparation), ferric citrate solutions were 
incubated in Claycomb medium with confluent HL-1 cardiomyocytes for 24 hours. 
When ferric ammonium citrate (FAC) was used, it was added as freshly prepared 
(from solids) to the experimental media. Freshly dissolved ferric ammonium citrate 
is a 1:2 Fe:citrate ratio ferric citrate (i.e. constant ratio ferric citrate) with inert 
ammonium cations in solution15. For the sake of simplicity we have not used 
albumin alongside ferric citrate to model NTBI. 
Ferrotransferrin preparation 
In order to produce diferric transferrin, apotransferrin was saturated using ferric 
nitrilotriacetate (Fe-NTA) in excess of transferrin binding (or to 95%) with 
subsequent 24h dialysis against 2L of PBS using 10,000 MWCO Slide-A-Lyzer 
Dialysis Cassette (Thermo Scientific) to remove excess iron and NTA. Transferrin 
saturation solutions were prepared by mixing thus obtained diferric transferrin with 
calculated amounts of MOPS-buffered apotransferrin in 25mM bicarbonate to 
obtain the nominal % saturation of transferrin. In this model of transferrin 
saturation, the monoferric transferrin species are not present, which may be 
considered a limitation of this model, however in our experiments we wished to 
address the nascence of apotransferrin which, unlike the monoferric species, is the 
consequence of uptake and recirculation of diferric (and monoferric) transferrin by 
the erythron16.  
The viability of HL-1 cardiomyocytes, in the presence of 0-30µM buffered ferric 
citrate ± 5µM apotransferrin, was 96.6±0.7%, as assessed by the electric current 
exclusion method on CASY Model TT Cell Counter and Analyzer (Roche). 
Cellular iron assays 
 
Total cellular iron was assayed by ferrozine using previously published methods17. 
Briefly, following incubation of cell monolayers in experimental media, cells were 
washed 3-4 times with PBS (including one wash with DFO- or CP40-containing 
PBS to remove membrane associated iron). Washed monolayers were then lysed 
with 200µL of 200mM NaOH and left overnight on a plate shaker. A 100µL aliquot 
of the lysate was added to 100µL of 100µM HCl (standard solution matrix) and 
treated with 100µL of a freshly prepared iron-extracting solution (1:1 vol/vol 5% 
KMnO4/1.4M HCl) for 2h at 60°C under fume hood extraction. This was followed 
by the addition of 30µL of a freshly prepared iron-detecting solution, containing 
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6.5mM ferrozine, 6.5mM neocuproine, and 1M ascorbic acid in 2.5M ammonium 
acetate, and the mixture was incubated for 30 minutes at room temperature on an 
orbital plate shaker. The absorbance of the ferrozine-iron complex was measured at 
562nm using a plate-reader. Results were interpolated from a standard curve 
obtained using atomic absorption ferric chloride standards and 100µL of 200mM 
NaOH (lysate matrix) and reported as cell lysate iron concentration (µM). 
 
Reactive Oxygen Species assay 
 
The intracellular reactive oxygen species (ROS) assay was performed using 2,7-
dichlorofluorescein diacetate (H2DCF-DA), which is de-esterified intracellularly by live 
cells to 2,7-dichlorofluorescein (DCF). 9µM H2DCF-DA in DMSO/PBS was added to 
confluent HL-1 monolayers after PBS rinse and incubated for 30 min in 48-well plates 
at 37°C and 5% CO2. Following three PBS rinses, 500µL PBS aliquot was added with 
100µM CP40 or 5µM apotransferrin (final concentration). CP40 chelator was used as a 
control for extra-cellular chelation18. Immediately afterwards, ferric citrate, buffered in 
MOPS pH=7.4, was added to a final concentration of 0-30µM. Fluorescence was 
monitored for 60 minutes (excitation 493nm, emission 523nm). Slopes, shown as 
mean±SD, were calculated from fluorescence-versus-time data to represent the 
cytosolic ROS formation over 1h using linear regression. 
The extracellular chelator CP40 was a kind gift from Professor Robert Hider, KCL. 
All chemicals were from Sigma-Aldrich apart from 0.05% trypsin-EDTA, L-
glutamine, streptomycin and penicillin (Life Technologies), soybean trypsin 
inhibitor (Invitrogen), atomic absorption ferric chloride standard (Aldrich), 
ammonium acetate (Fisher) or if otherwise stated. 
Supplemental Figures:  
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Supplement Figure 1. The correlations and regressions of soluble transferrin 
receptor-1 (sTfR1) with markers of iron overload, hepcidin and GDF-15. 
(A) Relationship of serum ferritin and sTfR1, linear regression slope p=0.52. (B) 
Relationship of hepatic R2* with sTfR1, linear regression slope p=0.4. (C) 
Relationship of plasma hepcidin and sTfR1, Spearman correlation coefficient r= -
0.54, p<0.0001; power series regression y=20.06[±2.09]x-0.37[±0.09]. (D) Relationship 
of GDF-15 and sTfR1, linear regression slope p=0.04. 
 
 
Supplement Figure 2. Dose response of iron retention in HL-1 cells to 
transferrin saturation. 
Confluent HL-1 cardiomyocytes were incubated for 24h with Claycomb medium, 
containing 36.5µM transferrin concentration, with transferrin saturation obtained by 
mixing diferric transferrin to apotransferrin at specified ratios, mean±SD, n=6; see 
methods. 
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Supplemental Figure 3. The relationship of patient history factors to sTfR1 in 
TDT. (A) Regression of sTfR on the age when chronic transfusion was started, 
slope p<0.0001. (B) Regression of sTfR on age at diagnosis, slope p=0.47. (C) 
Regression of sTfR on the total duration of transfusion dependence, slope p=0.07. 
(D) Regression of sTfR on patient’s age, slope p=0.77. 
 
 
Supplemental Figure 4. Labile plasma iron for ferric nitrilotriacetate and 
ferric citrate species is shown. 
Labile plasma iron (LPI) assay performed using 0-10µM ferric nitrilotriacetate and 
0-10µM ferric citrate at constant citrate (100µM), mean±SD, n=2; see methods. 
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